Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance  by Kaysen, G.A.
Kidney International (2007) 72       779
commentar yhttp://www.kidney-international.org
© 2007 International Society of Nephrology
Dialysis removes apolipoprotein 
C-I, improving very low-density 
lipoprotein clearance
GA Kaysen1–3
Chronic kidney disease (CKD) is associated with dyslipidemia, 
characterized by increased levels of triglyceride-rich lipoproteins 
(TRLPs), including very low-density lipoprotein (VLDL) and 
intermediate-density lipoprotein (IDL), with no change or a reduction 
in low-density lipoprotein (LDL) and low high-density lipoprotein 
(HDL) levels. Serum triglycerides and IDL are risk factors for vascular 
disease in dialysis patients, whereas LDL is not. The principal cause of 
the increase in TRLPs is decreased removal, not increased synthesis. 
The clearance defect arises from a reduction in specific lipoprotein 
receptors, decreases in the activity of lipases, and increased levels of 
low-molecular weight apolipoproteins that inhibit the interaction 
between TRLPs and both the receptors and the lipases that catabolize 
them. VLDL from dialysis patients is structurally abnormal and is not 
metabolized at a normal rate by lipoprotein lipase (LPL). 
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Dautin et al. establish that apolipoprotein 
C-I (apoC-I), a potent inhibitor of 
lipoprotein lipase (LPL) and of the 
engagement of triglyceride-rich lipo-
proteins (TRLPs) with the lipoprotein-
like receptor, is removed speciﬁcally from 
very low-density lipoprotein (VLDL) by 
dialysis, normalizing the aﬃnity between 
VLDL and LPL. Because apoC-I is also 
an inhibitor of cholesterol ester transfer 
protein, an enzyme that may accelerate 
degradation of high-density lipoprotein 
(HDL), its removal could potentially 
further depress HDL levels. Fortunately, 
this was not observed. Thus, dialysis 
could potentially correct aspects of 
chronic kidney disease (CKD)-associ-
ated dyslipidemia.
The risk of death from cardiovascu-
lar disease among patients with CKD is 
increased between three- and tenfold com-
pared with that among the general popu-
lation.1 This increased risk occurs even 
prior to initiation of dialysis.2 Although 
total cholesterol levels3 and low-density 
lipoprotein (LDL) cholesterol levels4 are 
not predictive of mortality, disorders in 
other lipoprotein components, notably 
increased triglyceride levels,5 VLDL, and 
intermediate-density lipoprotein (IDL), are 
associated with aortic stiﬀness, an indica-
tor of vascular injury.6 Decreased HDL 
cholesterol level is also associated with 
cardiovascular disease in CKD patients.7,8 
Thus two lipoprotein-related risk factors, 
low HDL and high levels of non-LDL, non-
HDL lipoproteins, remain risk factors for 
vascular disease among dialysis patients.
The lipid disorders of CKD are 
represented more by a dyslipidemia than 
by hyperlipidemia. In many regards, dis-
ordered lipid metabolism of kidney failure 
resembles that of the metabolic syndrome. 
Despite the increased prevalence of the 
metabolic syndrome among patients with 
CKD, there are signiﬁcant diﬀerences in the 
mechanisms responsible for establishing 
the levels of speciﬁc lipoprotein subclasses.9 
Whereas, in the metabolic syndrome, dys-
lipidemia and hyperlipidemia arise mostly 
from increased lipoprotein synthesis, spe-
ciﬁcally that of triglyceride-rich VLDL1, 
the dyslipidemia of CKD, speciﬁcally of 
the apolipoprotein B (apoB)-containing 
lipoproteins, is characterized by reduced 
clearance.10 This may contribute to their 
increased atherogenicity, as long-lived lipo-
proteins are more subject to oxidation.11
VLDL is synthesized by the liver and 
chylomicrons by the intestines. They 
carry with them, among others, apoE 
and apoC-I through III (Figure 1). ApoE 
engages with a variety of receptors (VLDL 
receptor and the lipoprotein-like recep-
tor (LRP), as well as enzymes, including 
LPL necessary for lipolysis.12 The levels of 
several lipoprotein receptors are reduced 
in CKD,13 as is LPL,12 combining to 
reduce the clearance of VLDL and IDL. 
However, decreased clearance of these 
lipoproteins is due not only to a reduc-
tion in LPL and receptor levels, but also 
to intrinsic defects in the capacity of lipo-
proteins harvested from CKD patients to 
act as appropriate substrates for lipolytic 
enzymes,14 providing yet a third mecha-
nism prolonging the half-life of these 
lipoproteins. Dautin and co-workers15 
(this issue) now address potentially cor-
rectable mechanisms responsible for this 
defect in lipoprotein structure.
ApoC-I and C-III are both increased in 
CKD, and both apolipoproteins inhibit the 
interaction between these lipoproteins and 
their receptors.16 ApoE is a ligand eﬀecting 
binding of TRLPs to the LRP, to the VLDL 
receptor, and to LPL. ApoC-I disrupts the 
interaction between apoE and lipoprotein 
receptors17 and is also a powerful inhibi-
tor of LPL,18 reducing the activity of the 
already reduced levels of this enzyme. Thus 
dialysis patients face three hurdles in the 
path of clearance of TRLPs: reduced recep-
tor numbers, inhibition of LPL, and com-
petitive interference with binding of the 
lipoproteins to their sites of catabolism.
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HDL levels are primarily established by 
the rate of HDL catabolism. This in turn is 
linked to HDL density or size. Renal failure 
is characterized by small HDL size and, in 
contrast to metabolism of the TRLPs, an 
increased catabolic rate.9 HDL matura-
tion is impaired by low lecithin cholesterol 
acyltransferase (LCAT) activity in dialysis 
patients,19 yielding small dense rapidly cat-
abolized β-migrating HDL. The ﬁnal step 
in HDL maturation is an exchange of its 
cholesterol ester-rich core for triglycerides 
carried by VLDL remnants by cholesterol 
ester transfer protein (CETP) producing 
LDL and small dense α-migrating HDL3. 
Like β-migrating HDL, HDL3 is also cat-
abolized at an increased rate, causing low 
HDL levels (Figure 1). ApoC-I inhibits 
CETP.20 Thus decreasing apoC-I levels 
could potentially result in an accelera-
tion of this reaction, such as occurs in the 
metabolic syndrome,9 causing a further 
decline in HDL in dialysis patients beyond 
that associated with reduced LCAT activity 
alone as a consequence of the removal of an 
endogenous CETP inhibitor. Thus removal 
of apoC-I could have an adverse eﬀect.
The low atomic mass of these apolipo-
proteins (apoC-I 6630.6 daltons and 
apoC-III 8765.7 daltons21) makes them 
potential targets for removal by dialysis. 
Dautin and co-workers15 have carefully 
established that dialysis selectively removes 
apoC-I from the VLDL pool, improving its 
capacity as a substrate for LPL, while not 
aﬀecting the HDL apoC-I pool. This was 
possible because of the relationship of the 
duration of dialysis treatments to the rela-
tively rapid half-life of VLDL (hours) as 
compared with that of HDL (days). This 
suggests that dialysis is removing a labile 
apoC-I pool and that lipoprotein structure 
is changed by replacement of abnormally 
structured lipoproteins with newly formed 
normally structured isoforms during dialy-
sis. CETP activity was also not increased, 
suggesting that it is the apoC-I delivered to 
this enzyme by HDL and not by the VLDL 
substrate that inhibits CETP activity. For-
tunately, HDL metabolism was unaltered.
After dialysis, VLDL was a better sub-
strate for LPL than was VLDL obtained 
before dialysis, suggesting that VLDL 
obtained after dialysis was newly formed 
and that the uremia-associated alteration in 
the structure of VLDL that makes it a poor 
substrate for LPL is mediated by a sub-
stance that can be removed during dialysis, 
most likely apoC-I. The eﬀect of dialysis on 
either the removal of or the level of IDL, 
the highly atherogenic remnants of both 
VLDL and chylomicron metabolism, was 
not explored; however, because the half-
life of IDL is shorter than that of VLDL, 
any contribution of decreased apoC-I to 
the removal of IDL should also have been 
aﬀected by dialysis.
ApoC-I inhibits binding of β-migrat-
ing VLDL to the LRP22 and impairs the 
clearance of both VLDL and CM remnant 
particles. Additionally, hepatic LRP gene 
regulation is downregulated in CKD.13 
Increased apoC-I levels in conjunction 
with decreased receptor numbers then pro-
vide a double defect conspiring to increase 
the levels of these atherogenic lipoproteins. 
Thus dialysis patients have a dual defect in 
that the enzymes necessary for catabo-
lism of TRLPs are reduced while at the 
same time inhibitors of these enzymes and 
receptors found on the lipoprotein targets 
are increased. Dialysis appears to play a role 
in reducing at least one of these defects.
Eﬀective treatment strategies for reduc-
ing cardiovascular risk among dialysis 
patients have been elusive. The use of 
statins to reduce LDL cholesterol was of 
small and statistically insigniﬁcant ben-
eﬁt.23 ApoC-I levels returned to baseline 
by 24 hours; however, prolonged or daily 
dialysis might have the potential to nor-
malize metabolism of the TRLPs and thus 
reduce cardiovascular risk.
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Figure 1 | Very low-density lipoprotein (VLDL) is secreted by the liver and chylomicrons (CM) 
by the intestine, containing apolipoprotein E (apoE) and apoC-I, C-II, and C-III. Triglycerides 
are lipolized on the vascular endothelium by lipoprotein lipase (LPL) that is bound there to 
heparan sulfate proteoglycans (HSPG). CM remnants engage the lipoprotein-like receptor 
(LRP) through an apoE bridge and are taken up by the liver. VLDL remnants follow the same 
path or are converted into low-density lipoprotein (LDL) through interaction with high-density 
lipoprotein (HDL) by the enzyme cholesterol ester transfer protein (CETP) and are taken up 
by the LDL receptor. HDL is composed of apoA-I and apoA-II secreted by liver and gut and 
acquires cholesterol interacting with lipid-laden macrophages through the ATP-binding 
cassette A1 (ABCA1). The nascent β-migrating HDL is matured by action of lecithin cholesterol 
acyltransferase (LCAT) in a stepwise manner to the large HDL2 isoform that either is taken up by 
the liver, interacting with the HDL receptor (SR-B1), or transfers its core to the VLDL remnant, 
creating LDL and more rapidly metabolized small HDL3. In chronic kidney disease (CKD), 
expression of the LRP is reduced, LPL levels are reduced on the vascular endothelium, and 
apoC-I and C-III inhibit LPL activity as well as interaction between apoE and both the LRP and 
LPL. HDL maturation is impaired because of decreased levels of LCAT. Enzymes and pathways 
that are adversely affected in CKD are indicated in red. IDL, intermediate-density lipoprotein.
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Hypertension in connexin40-null 
mice: a renin disorder
DC Spray1
Studies described in this issue indicate that the gap junction protein 
connexin40 (Cx40) appears to play an unexpected role in blood pressure 
regulation. In mice lacking this gap junction protein, renin secretion is 
high and not regulated by arteriolar pressure.
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Gap junction channels uniquely fulfill 
the vital role of providing a pathway for 
intercellular diﬀusion of ions and small 
molecules between coupled cell popula-
tions within a tissue. In chordates, these 
channels are formed by connexin pro-
teins, a family of about 20 members in 
mammals, where expression of isoforms 
is cell type and tissue speciﬁc, with some 
overlap. The biophysical properties of 
channels formed by individual connexins 
vary, as do those of proteins that bind to 
the connexins; this presumably confers 
diﬀerences tuned to match the function 
that these channels serve in various tis-
sues, such as second messenger exchange 
in the liver and perhaps astrocytes in the 
brain, electrical signal propagation in excit-
able systems such as the heart, brain, and 
pancreatic islet, and metabolite exchange in 
the lens. Because of the tissue-speciﬁc dis-
tribution of connexins and the well-known 
exchange of ions and signaling molecules 
through them, connexin-null mice might 
have been expected to have well-predicted 
and perhaps quite restricted phenotypes. 
For example, the ventricles of mice lacking 
connexin43 (Cx43) might be expected to 
beat arrhythmically because of loss of the 
most abundant gap junction protein, the 
liver of Cx32-null mice might be dysfunc-
tional because of lack of signaling between 
periportal and perivenous hepatocytes, 
and Cx50 knockouts might be expected 
to display cataracts. In fact, although these 
changes are seen to one extent or another 
as part of the overall mouse phenotype, 
the major changes in the animals are dif-
ferent, revealing hitherto unsuspected (and 
to some degree still not well understood) 
roles of the individual connexins in the ani-
mal. Cx43-null mice die at birth as a result 
of congenital malformation in the right 
ventricle, blocking outflow to the lung; 
Cx32-null mice display reduced peripheral 
myelination (now known to be the genetic 
